What are the recommendations for a woman of child‑bearing age taking levetiracetam (Keppra) who is planning pregnancy regarding continuation of the drug, dosing, folic acid supplementation, and possible alternative antiepileptic options?

Levetiracetam and Planning of Pregnancy

Women of childbearing age taking levetiracetam who are planning pregnancy should continue the medication (as it is among the safest antiepileptic drugs for pregnancy), supplement with 0.4-0.8 mg (400-800 mcg) of folic acid daily starting at least 1 month before conception, and monitor drug levels during pregnancy as levetiracetam clearance increases significantly, particularly in the third trimester.

Continuation of Levetiracetam

Levetiracetam is one of the preferred antiepileptic drugs during pregnancy. The FDA label indicates it is Pregnancy Category C, but critically notes that "discontinuation of antiepileptic treatments may result in disease worsening, which can be harmful to the mother and the fetus" 1. The risk of uncontrolled seizures during pregnancy typically outweighs the teratogenic risks of levetiracetam, particularly when compared to alternatives like valproate or carbamazepine.

Recent evidence supports levetiracetam's favorable safety profile:

• Among 147 pregnancies exposed to levetiracetam, only 2% experienced major congenital malformations, and all occurred in women taking polytherapy (not monotherapy) 2
• Levetiracetam appears comparatively safer than valproate and topiramate, with a risk profile similar to lamotrigine 3, 4
• Expert consensus from 2022 indicates levetiracetam "seems to be a good alternative, working well against focal and generalized seizures" during pregnancy 5

Do not discontinue levetiracetam when planning pregnancy. The medication should be continued at the lowest effective dose that maintains seizure control.

Folic Acid Supplementation

All women taking antiepileptic drugs who are planning pregnancy require higher-dose folic acid supplementation than the general population. The USPSTF guidelines specifically note that their standard 0.4-0.8 mg recommendation "does not apply to women taking certain antiseizure medicines" 6.

Recommended Dosing Strategy:

• Standard recommendation for women on levetiracetam: 1-2 mg daily 7

  • This reflects current international expert consensus (73% of experts recommend 1-2 mg daily for women with epilepsy on antiepileptic drugs)
  • Begin at least 1 month before conception, ideally 3 months before 8
  • Continue through the first trimester

• Higher doses (4-5 mg daily) are reserved for:

  • Women taking valproate (not applicable here) 9
  • Women with prior neural tube defect-affected pregnancy 10
  • Women on enzyme-inducing antiepileptic drugs 7

Critical timing consideration: Folic acid must be started before conception because neural tube closure occurs within the first month after conception, before most women know they are pregnant 10. Recent data shows only 65.6% of women with epilepsy actually take high-dose folic acid before conception 11, highlighting the importance of proactive counseling.

Dose Monitoring and Adjustment

Levetiracetam levels should be monitored during pregnancy because clearance increases significantly, particularly in the third trimester 8. This is primarily due to increased renal blood flow during pregnancy 2.

Monitoring Protocol:

1. Obtain baseline level before conception (if possible)
2. Monitor levels during each trimester, especially mid-third trimester 2
3. Increase dose as needed to maintain pre-conception therapeutic concentrations
4. Plan for postpartum dose reduction back to pre-pregnancy levels after delivery

The American Academy of Neurology recommends that "monitoring of levetiracetam levels may be considered (Level C)" during pregnancy 8. While not the strongest evidence level, this is clinically prudent given the known pharmacokinetic changes.

Alternative Antiepileptic Options

While levetiracetam is already a preferred option, understanding alternatives is important:

Lamotrigine is the other first-line option for pregnancy:

• Similar low malformation rate when used at <325 mg daily 3
• However, levels drop by >50% during pregnancy due to estrogen effects, making seizure control more difficult 5, 3
• May have promyoclonic effects in some patients with certain epilepsy types 3

Avoid these medications:

• Valproate: Highest malformation risk (5.2-fold increased autism risk, 2.9-fold increased autism spectrum disorder risk) 3
• Carbamazepine: Increased neural tube defect risk, specifically mentioned in USPSTF guidelines 6
• Topiramate: Higher malformation risk 3
• Phenytoin, oxcarbazepine: Should be avoided 3

If seizures are not controlled on levetiracetam monotherapy, combination therapy with lamotrigine plus levetiracetam offers "the chance of seizure control and lesser risks of major congenital malformations" compared to other combinations 3.

Common Pitfalls to Avoid

1. Waiting until pregnancy is confirmed to start folic acid - Neural tube closure occurs by day 28 post-conception
2. Using standard 0.4 mg folic acid dose - Women on antiepileptic drugs need higher doses (1-2 mg minimum)
3. Failing to monitor drug levels during pregnancy - Levetiracetam clearance increases substantially
4. Switching from levetiracetam to lamotrigine during pregnancy planning - Both are acceptable first-line options; unnecessary switching adds risk
5. Not planning for postpartum dose adjustment - Levels will rise after delivery as renal clearance normalizes

Breastfeeding Consideration

Levetiracetam "probably transfers into breast milk in amounts that may be clinically important" 8. However, this must be balanced against the benefits of breastfeeding. The decision should be individualized, but many experts support breastfeeding with close infant monitoring for sedation or feeding difficulties.

Pregnancy Registry Enrollment

Strongly encourage enrollment in pregnancy registries 1:

• North American Antiepileptic Drug Pregnancy Registry: 1-888-233-2334
• UCB AED Pregnancy Registry: 1-888-537-7734

This contributes to ongoing safety data collection and may provide additional monitoring support.